Jefferies Group’s Health Catalyst HCAT Stock Holding History

Jefferies Group’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$266K	Buy	+27,434	New	+$363K	﹤0.01%	1273

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Jefferies Group's HCAT Position: Q3 2022 in Review

Jefferies Group opened a new position in Health Catalyst (HCAT) in Q3 2022: 27,434 shares worth $266K. The stake represents ﹤0.01% of the portfolio and ranks #1273 among its holdings.

171 funds tracked by Wall St. Rank hold HCAT as of Q3 2022.

Jefferies Group held 27,434 shares of Health Catalyst worth $266K as of Q3 2022.
Health Catalyst was a new Jefferies Group position in Q3 2022.
Health Catalyst made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1273 holding.
171 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.